Ruth Adams
Chief Tech/Sci/R&D Officer bei NUVALENT, INC.
Profil
Ruth Adams is currently working as the Vice President-Clinical Operations at Nuvalent, Inc. Prior to this, she worked as the Head-Clinical Operation at Vigeo Therapeutics, Inc. Ms. Adams completed her undergraduate degree from The University of Southampton.
Aktive Positionen von Ruth Adams
Unternehmen | Position | Beginn |
---|---|---|
NUVALENT, INC. | Chief Tech/Sci/R&D Officer | 01.11.2020 |
Ehemalige bekannte Positionen von Ruth Adams
Unternehmen | Position | Ende |
---|---|---|
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Ruth Adams
The University of Southampton | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
NUVALENT, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | Health Technology |